



FLORICANNABIS CONEXÕES

UMA PONTE ENTRE CIÊNCIA E SAÚDE.





Para onde a planta levou minha medicina...



Para onde a planta levou minha medicina...





















Ziller Victor Ramires da Silva

★ 26.03.1935
† 04.06.2018

*"Eu não estou longe,
apenas estou do outro lado do Caminho...
Você que aí ficou, siga em frente,
a vida continua,
linda e bela como sempre foi."
(Santo Agostinho)*

*Que o eterno, em sua infinita misericórdia,
te receba de braços abertos.*

Nós te amaremos sempre!






Ressonância Nuclear Magnética do Crânio (corte coronal)

Pacientes masculinos DRAVET (SCN1A) 16 anos de idade


Caso 6

Medicação alopática



Beni

Após 10 anos de uso Medicinal Cannabis








LEANDRO RAMIRES
CANNABIS MEDICINAL



1.932 Pacientes (set/2019 - jun/2025)

Inicio de prescrição mar/2014. Próximo de 4.000 pacientes atendidos






LEANDRO RAMIRES
CANNABIS MEDICINAL



“MEDICINA ENDOCANABINOIDE”




Protocolos de Acompanhamento



*“Nós não medicamos
doenças, nós
auxiliamos o SEC na
busca da
homeostase”*





Grupo AMA+ME
Associados epiléticos refratários
usuários de
Óleo de cannabis rico em CBD

CERTIFICADO
CERTIFICATE

CONFIRMAMOS QUE O ESTUDO:
ESTUDO OBSERVACIONAL
ESTUDO DE ÓLEO DE CANNABIS RICO EM CANNABIDIOL PARA CONTROLE DE EPILEPSIA REFRATÁRIA:
ESTUDO OBSERVACIONAL
RESUMO: UNAMERICO CRUZ MAMBRASSA SILVA; PRIMO DA COSTA MELLO NETO; PRIMATO; MARCILSON LOPES;
PAULO FILSOLY TEIXEIRA, foi apresentado, na sessão de Trabalhos Livres ABEMEP, no evento II CONGRESO
INTERNACIONAL Y XXV BRASILENO DA ABEMEP, XXII CONGRESO ANUAL DE LA ABEP Y CONGRESO
INTERAMERICANO DE PLATA, dentro de 09 a 12 de setembro de 2015 no Centro de Convenciones de Jujuy Convention Center em
Córdoba da Argentina.





Parâmetro

1 – Redução do número de crises convulsivas (>50%)	78,9%
2 – Redução na intensidade das crises convulsivas	94,7%
3 – Redução no uso de drogas anticonvulsivantes	73,0%
4 – Redução de internações hospitalares	83,0%
5 – Redução de atendimentos de urgência / emergência	87,0%
6 – Ganho importante na evolução psicomotora	42,1%

Efeitos colaterais: sonolência (21,1%), aumento de apetite (5,3%) e diarreia leve (2,8%)
Extratos ricos em CBD de 6 origens diferentes



frontiers
in Neurology | Neuropharmacology

SECTION ABOUT ARTICLES RESEARCH TOPICS FOR AUTHORS EDITORIAL BOARD ARTICLE ALERTS

◀ Articles THIS ARTICLE IS PART OF THE RESEARCH TOPIC
Cannabinoid Therapeutics: What's Hot [View all 24 Articles](#) >

ORIGINAL RESEARCH ARTICLE Provisionally accepted The full-text will be published soon. [Notify me](#)
Front. Neurol. | doi: 10.3389/fneur.2019.01145


Effects of CBD-enriched Cannabis sativa extract on Autism Spectrum Disorder symptoms: an observational study of 18 participants undergoing compassionate use


Paulo Fleury-Teixeira¹, Fabio V. Caixeta², Leandro C. Ramires da Silva^{3,4}, Joaquim P. Brasil-Neto² and Renato Malcher-Lopes^{2*}

¹ePrimeCare Healthcare SA, Brazil
²Department of Physiological Sciences, University of Brasília, Brazil
³Clinical Hospital, Federal University of Minas Gerais, Brazil
⁴Associação Brasileira de Pacientes de Cannabis Medicinal, Brazil



Indicador	Percepção de melhora (%)
<i>Attention Deficit / Hyperactivity Disorder</i>	30%
<i>Behavioral disorders</i>	20%
<i>Motor deficits</i>	20%
<i>Autonomy Deficits</i>	10%
<i>Communication Deficits and Social Interaction</i>	25%
<i>Cognitive deficits</i>	20%
<i>Sleep disorders</i>	40%
<i>Convulsive Seizures (n=5)*</i>	100% CS







ORIGINAL RESEARCH article

Front. Psychiatry

Sec. Psychopharmacology

Volume 14 - 2023 | doi: 10.3389/fpsy.2023.1210155

This article is part of the Research Topic

Insights on Cannabinoid Translational Science and Medicine: The Endocannabinoidome as a Target for Clinical Practice

[View all 4 Articles >](#)

Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits

Patrícia Montagner¹  Wesley Medeiros²  Leandro R. da Silva^{3,4} Clarissa N. Borges⁵  Joaquim P. Brasil-Neto⁶

 Vinícius d. Barbosa^{7,8}  Fabio V. Caixeta⁹  Renato Malcher-Lopes^{9*}

¹ NeuroVinci Clinic, Brazil

² University of Brasília, Brazil

³ Clinical Hospital, Federal University of Minas Gerais, Brazil

⁴ Associação Brasileira de Pacientes de Cannabis Medicinal, Brazil


⁵ Specialized Educational Care Division for Gifted Students of the Department of Education of the Federal District, Brazil

⁶ Unieuro, Brazil

⁷ Medicinal Cannabis Center, Sírio-Libanês Hospital, Brazil

⁸ National Association for Inclusion of the Autistic Person, Brazil

⁹ Laboratory of Neurosciences and Behavior, Department of Physiological Sciences, Institute of Biological Sciences, University of Brasília, Brazil





Restrição alimentar
Dependência para a vida diária
Deficiência intelectual
Tristeza, melancolia e mau humor
Atraso no desenvolvimento motor / Coordenação
Agitação
Interação prejudicada comunicação (verbal / não verbal)
Convulsões
Comportamento anormal
TDAH
Insônia
Melhora geral da família do paciente
Melhora geral do paciente







FIGURE 2

Perceived effects of FCE treatment over main symptom categories and aspects of ASD as percentages of the cohort. Percentages were rounded to whole numbers for clarity. Avoidance and/or restrictions of food intake (ARFI, $n = 15$); Lack of independence for daily activities (DDA, $n = 18$); Intellectual and cognitive performance deficits (CD, $n = 16$); Sadness, melancholy and bad moods (SMBM, $n = 17$); Impaired motor development and motor coordination (MD, $n = 15$); Positive mood states (PM, $n = 19$); Impaired communication and personal interactions (verbal and non-verbal; CPI, $n = 18$); Seizures (SZ, $n = 6$); Abnormal behaviors in general (AB, $n = 18$); Attention deficits/ hyperactivity disorder (ADHD, $n = 19$); Sleep issues (SI, $n = 13$); Overall family's quality of life (FQoL, $n = 20$); Overall patient's quality of life (PQoL, $n = 20$).









OXFORD ACADEMIC Journals Books

Pain Medicine

Issues More Content ▾ Publish ▾ Purchase Advertise ▾ About ▾ Pain Medicine ▾ Advanced Search

JOURNAL ARTICLE

Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 

Carolina Chaves, MD , Paulo Cesar T Bittencourt, MD, MSc, Andreia Pelegrini, PhD

Pain Medicine, Volume 21, Issue 10, October 2020, Pages 2212–2218,
<https://doi.org/10.1093/pain/pnaa303>

Published: 28 October 2020

Article Contents

Abstract

PDF Views ▾ Cite Permissions Share ▾

Pain Medicine
Why publish with Pain Medicine?

TOP 5 REASONS TO SUBMIT

OXFORD UNIVERSITY PRESS

Advertisement







Table 1. Comparison of mean scores on FIQ between groups

Study Variable	Pre-intervention		P Value	Postintervention		P Value*
	Cannabis x̄ (sd)	Placebo x̄ (sd)		Cannabis x̄ (sd)	Placebo x̄ (sd)	
FIQ (0–100)	75.50 (12.93)	70.22 (11.18)	0.381	30.50 (16.18)	61.22 (17.30)	0.005
Physical function (0–10)	6.37 (1.88)	4.03 (2.08)	0.021	5.83 (2.02)	4.07 (2.25)	0.139
Feel good (0–10)	9.47 (1.06)	9.68 (0.95)	0.673	1.73 (0.64)	7.50 (2.93)	0.002
Work missed (0–10)	5.10 (3.86)	7.14 (4.95)	0.517	2.38 (1.65)	6.57 (3.29)	0.071
Job ability (0–10)	7.13 (2.90)	7.89 (2.15)	0.606	4.29 (1.70)	7.89 (1.36)	0.001
Pain (0–10)	8.25 (1.98)	8.67 (2.96)	0.481	3.75 (2.49)	7.67 (1.84)	0.006
Fatigue (0–10)	8.00 (2.07)	7.33 (3.39)	0.963	4.00 (2.08)	6.11 (3.37)	0.174
Morning tiredness (0–10)	7.88 (1.42)	8.33 (2.06)	0.815	4.50 (1.91)	7.67 (3.16)	0.106
Stiffness (0–10)	7.75 (2.05)	6.11 (2.84)	0.236	3.33 (3.21)	5.00 (3.91)	0.482
Anxiety (0–10)	8.38 (1.69)	8.00 (2.00)	0.743	7.00 (2.92)	7.00 (2.87)	0.898
Depression (0–10)	7.50 (2.45)	7.78 (2.49)	0.815	5.80 (3.11)	4.67 (3.84)	0.699

FIQ = Fibromyalgia Impact Questionnaire; \bar{x} = average value; sd = standard deviation.

*Mann-Whitney test (nonparametric data). There were significant reductions in total FIQ score and on the "feel good," "job ability," and "pain" items in the cannabis group compared with the placebo group. The cannabis group initially presented a significantly greater score on the "physical impairment" item.





Pesquisa

Clínica Veterinária

(Produção Científica)



OPEN ACCESS

EDITED BY

Wayne S. Schwark,
Cornell University, United States

REVIEWED BY

Catarina Jota Baptista,
Universidade de Trás os Montes e Alto
Douro, Portugal
Elena Dalle Vedove,
CIAM S.r.l, Italy

***CORRESPONDENCE**

Carollina Mariga
✉ carollina.mariga@hotmail.com

RECEIVED 29 August 2023

ACCEPTED 09 October 2023

PUBLISHED 31 October 2023

CITATION

Mariga C, Souza Silva Mateus AL, dos Santos
Dullius ÁL, da Silva AP, Martins Flores M,
Vasconcelos Soares A, Amazonas E and Tadeu
Lemos Pinto Filho S (2023) Dermatological
evaluation in dogs with atopic dermatitis

TYPE Original Research
PUBLISHED 31 October 2023
DOI 10.3389/fvets.2023.1285384

Dermatological evaluation in dogs with atopic dermatitis treated with full-spectrum high cannabidiol oil: a pre study part 1

Carollina Mariga^{1*}, Ana Lúcia Souza Silva Mateus²,
Ângela Isabel dos Santos Dullius², Ana Paula da Silva³,
Mariana Martins Flores⁴, André Vasconcelos Soares⁵,
Erik Amazonas⁶ and Saulo Tadeu Lemos Pinto Filho⁵

¹Programa de Pós-Graduação em Medicina Veterinária pela Universidade Federal de Santa Maria (UFSM),
Santa Maria, Rio Grande do Sul, Brazil, ²Departamento de Estatística na UFSM, Santa Maria, Rio Grande
do Sul, Brazil, ³Departamento de Clínica Médica no Hospital Veterinário Universitário da UFSM, Santa
Maria, Rio Grande do Sul, Brazil, ⁴Laboratório de Patologia Veterinária (LPV-UFSM), Santa Maria, Rio
Grande do Sul, Brazil, ⁵Departamento de Clínica de Pequenos Animais, Santa Maria, Rio Grande do Sul,
Brazil, ⁶Departamento de biociências e saúde única da Universidade Federal de Santa Catarina (UFSC),
Curitibanos, Santa Catarina, Brazil



Frontiers in Veterinary Science

TYPE Case Report

PUBLISHED 09 February 2024

doi 10.3389/fvets.2024.1309167

Check for updates

OPEN ACCESS

EDITED BY

Heather Knych,
University of California, Davis, United States

REVIEWED BY

Claudia Interlandi,
University of Messina, Italy
Stephen White,
University of California, Davis, United States

*CORRESPONDENCE

Marcy Lancia Pereira
✉ marcy.pereira@ufsc.br

Case report: Cannabinoid therapy for discoid lupus erythematosus in a dog


Maria Eduarda Schmitz da Silva¹, Bruna Christianetti¹,
Erik Amazonas^{2,3} and Marcy Lancia Pereira^{2*}

¹Veterinary Medicine Student, Federal University of Santa Catarina (UFSC), Curitibanos, Brazil,

²Department of Biosciences and One Health, Center for Rural Sciences, Federal University of Santa Catarina (UFSC), Curitibanos, Brazil, ³Cannabis Development and Innovation Center (PODICAN/UFSC), Curitibanos, Brazil



Variação da concentração de **CBD** durante descarboxilação de **CBDA** em Extrato de Cannabis “Full Spectrum” aquecido a 120⁰ C por 4 horas









amame

Associação Brasileira de Pacientes
de Cannabis Medicinal



WeCann
Endocannabinoid
Global Academy

Leandro Ramires (BRA)

Médico cirurgião oncológico e mastologista, Leandro Ramires é Mestre em Saúde da Mulher e câncer de mama pela Faculdade de Medicina da UFMG, ex-coordenador e ex-preceptor do Setor de Mastologia do Hospital das Clínicas da UFMG. Prescritor de Cannabis para fins medicinais desde abril de 2014, possui ampla experiência no tratamento adjuvante de pacientes com epilepsia, autismo, dor crônica, Alzheimer, Parkinson, doenças autoimunes, câncer e em cuidados paliativos. Cultivador de Cannabis para fins medicinais com Salvo Conduto para seu filho Benício portador da Síndrome de Dravet.

Atualmente é Diretor Médico Científico da Ass. Bras. de Pacientes de Cannabis Medicinal (amame.org.br), pesquisador Clínico, coautor de Estudos que confirmaram o benefício da Cannabis Medicinal no tratamento dos sintomas do autismo, envolvido em Projetos de Pesquisa Clínica, Educação e Qualificação de médicos em Cannabis medicinal desde 2015, e também, Expert da Wecan Academy



Muito obrigado

@leandroramiresmd
leandro-ramires.reservio.com
ramiresleandro@gmail.com
leandro@amame.or.br



FLORICANNABIS CONEXÕES

